




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DFW

 TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/747,702
	Filing Date	December 30, 2003
	First Named Inventor	Sultan Ahmad
	Art Unit	1646
	Examiner Name	LI, RUIXIANG
Total Number of Pages in This Submission	Attorney Docket Number	ASZN0039-101 (A1807-2P US)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Statement under 37 CFR 3.73(b) with Table A (2pp.); Copy of the Assignment Executed by ALL Inventors to Astra Pharma Inc; Copy of the Corporate Name Change from Astra Pharma Inc. to AstraZeneca Canada Inc. Executed by Astra Pharma Inc; and Copy of Assignment from AstraZeneca Canada Inc. to National Research Council of Canada.
<div style="border: 1px solid black; padding: 5px;"> Remarks <div style="text-align: center; font-size: 1.2em; font-weight: bold;">BEST AVAILABLE COPY</div> </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Cozen O'Connor		
Signature			
Printed Name	Paul K. Legaard, Ph.D.		
Date	10 MAY 2006	Reg. No.	38,534

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Paul K. Legaard, Ph.D., Registration No. 38,534	Date	10 MAY 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

I hereby appoint:

☒ Practitioners at Customer Number: **52286** as my/our attorney(s) or agent(s) to prosecute the applications identified in the attached Table A, and to transact all business in the United States Patent and Trademark Office connected with said applications.

Address all telephone calls and correspondence to:

**Paul K. Legaard, Ph.D.
Cozen O'Connor
1900 Market Street
Philadelphia, PA 19103
Tel: 215-665-6914**

I am the:

☐ Applicant/Inventor.
☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Signature of Applicant or Assignee of Record

Respectfully submitted,
National Research Council

Date: 20 April 2006

By: Marielle Piché
Name: Marielle Piché
Title: Secretary General



BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, National Research Council of Canada, a corporation of Canada, states that it is:

☒ the assignee of the entire right, title, and interest of the patents/applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is 100% in the patents/applications identified in Table A.

☒ a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,
National Research Council

Date: 20 April 2006

By: Marielle Piché
Name: Marielle Piché
Title: Secretary General

TABLE A

Docket Nos.	Application No/Patent No.	Filing Date/Issue Date	Examiner/Group Art Unit	Title
ASZN0038-100 A1573-1PUS	6,562,945	May 13, 2003	S. Gucker/1647	Galanin Receptor
ASZN0038-101 A1573-2P US	10/359,285	February 6, 2003	To Be Determined/To Be Determined	Novel Galanin Receptor
ASZN0039-100 A1807-1P US	6,696,257	February 24, 2004	J. Murphy/1646	G-Protein-Coupled Receptors From the Rat and Human (as amended)
ASZN0039-101 A1807-2P US	10/747,702	December 30, 2003	R. Li/1646	Novel G Protein-Coupled Receptor

PATENT/Docket No.: N 1807-1P US

ASSIGNMENT TO ASTRA PHARMA Inc


Title: NOVEL G PROTEIN-COUPLED RECEPTOR
Inventors: Sultan Ahmad, Denis Banville, Yves Fortin, Paola
Lembo, Dajan O'Donnell and Shi-Hsiang Shen
U.S. Appl. No:
U.S. Filing Date:
Execution Date of Application:

As a below-named inventor, I hereby declare that:

My post office address is as stated below under my signature and I am named as inventor of the inventions or discoveries (herein INVENTIONS) as described in the patent application (herein APPLICATION) identified above. In view of valuable consideration, receipt thereof is hereby acknowledged, I do hereby assign and transfer unto ASTRA Pharma Inc., a corporation of Canada having a place of business at 1004 Middlegate Road, Mississauga, Ontario L4Y 1M4, Canada, its successors and assigns, my entire interest in and the full and exclusive right to the INVENTIONS, the APPLICATION and all related applications (including all divisions, reissues, continuations, and extensions thereof) and all counterparts in other countries, and any and all Letters Patent (and certificates of invention or similar certificates) (herein PATENTS) which may be granted based upon the INVENTIONS or the APPLICATION or related applications or counterparts in other countries; said transfer and assignment being applicable throughout the world. I hereby authorize and request officials of patent offices in any and all countries of the world to issue any and all of the PATENTS, when granted, to ASTRA Pharma Inc., its successors and assigns, as the assignee of my entire right, title, and interest in and to the same. I agree that I will communicate to ASTRA Pharma Inc., or its representatives, any facts known to me respecting the invention; testify in any legal proceedings; sign all lawful papers; execute all divisional, continuation, substitution, renewal, and reissue applications; execute all necessary assignment papers to cause any and all of the PATENTS to be issued to ASTRA Pharma Inc.; make all rightful oaths; and generally do everything possible to aid ASTRA Pharma Inc., its successors and assigns, to obtain and enforce proper protection for the INVENTION in any and all countries throughout the world.

BEST AVAILABLE COPY


FULL NAME OF FIRST/SOLE INVENTOR: Sultan Ahmad

Signature of Inventor: 

Address: Astra Research Centre Montreal, 7171 Fredrick-Banting, St Laurent, Quebec
H4S 1Z9, Canada

Date: Mar 16/99


FULL NAME OF SECOND/JOINT INVENTOR: Denis Banville

Signature of Inventor: 

Address: 595 Lajeunesse, Ste-Dorothee, Quebec H7X 3K4, Canada

Date: 16/3/99


FULL NAME OF THIRD/JOINT INVENTOR: Yves Fortin

Signature of Inventor: 

Address: 2985 Avenue Douglas, Montreal, Quebec H3R 2E2, Canada

Date: 16 mars 1999

FULL NAME OF FOURTH/JOINT INVENTOR: Paola Lembo

Signature of Inventor: 

Address: Astra Research Centre Montreal, 7171 Fredrick-Banting, St Laurent, Quebec H4S 1Z9,
Canada

Date: March 15, 99


FULL NAME OF FIFTH/JOINT INVENTOR: Dajan O'Donnell

Signature of Inventor: Dajan O'Donnell

Address: Astra Research Centre Montreal, 7171 Fredrick-Banting, St Laurent, Quebec H4S 1Z9, Canada

Date: March 16th 1999

FULL NAME OF SIXTH/JOINT INVENTOR: Shi-Hsiang Shen

Signature of Inventor: 

Address: 161 Charwell Crescent, Beaconsfield, Quebec H9W 1C2, Canada


Date: March 23, 1999


CANADA
PROVINCE OF ONTARIO
CITY OF TORONTO
TO WIT:

)
)
)
)
)
)


I, STEPHEN DOUGLAS BODLEY, a Notary Public in and for the Province of Ontario, by Royal Authority duly appointed, residing in the City of Toronto in the said Province DO HEREBY CERTIFY that the paper writing hereto annexed, the first page of which is stamped with an impression of my seal, is a true and correct photostatic copy of documents produced and shown to me out of custody of Blake, Cassels & Graydon LLP, Toronto, Ontario and purporting to be the original Certificate and Articles of Amendment of **ASTRAZENECA CANADA INC.** issued by the Ministry of Consumer and Commercial Relations and dated December 31, 1999, the said photostatic copy having been compared by me, page for page, with the said original documents, an act whereof being requested I have granted the same under my hand and notarial seal of office to serve and avail as occasion shall or may require.

DATED at Toronto this *13th* day of *March*, 2000.



A Notary Public in and for
the Province of Ontario



I **ANTHONY JANION GIBBS** of Wilmslow, Cheshire, England, Notary Public duly authorised admitted and sworn and practising within the United Kingdom of Great Britain and Northern Ireland **do hereby certify** that the photostat matter hereto annexed is a true copy of a document the original of which was produced to me at Macclesfield, Cheshire, England, this 22nd day of June in the year two thousand.



.....
Anthony Janlon Gibbs
Notary Public



CERTIFICATE

This is to certify that these
articles are effective on

DECEMBER 31

CERTIFICAT

Ceci certifie que les présents
statuts entrent en vigueur le

DÉCEMBRE, 1999

Ken D. Lin

Director / Directeur
Business Corporations Act / Loi sur les sociétés par actions

**ARTICLES OF AMENDMENT
STATUTS DE MODIFICATION**

**Form 3
Business
Corporations
Act**

Formule 3
Loi sur les
sociétés par
actions

1. The name of the corporation is:

Dénomination sociale de la société:

[illegible]

2. The name of the corporation is changed to (if applicable): *Nouvelle dénomination sociale de la société (s'il y a lieu):*

Nouvelle dénomination sociale de la société (s'il y a lieu):

[illegible]

- 3. Date of incorporation/amalgamation:**

Date de la constitution ou de la fusion:

1954 JUNE 28

(Year, Month, Day)
(année, mois, jour)

4. The articles of the corporation are amended as follows: *Les statuts de la société sont modifiés de la façon suivante.*

Les statuts de la société sont modifiés de la façon suivante.

To change the name of the Corporation to:

ASTRAZENECA CANADA INC.

5. The amendment has been duly authorized as required by Sections 168 & 170 (as applicable) of the Business Corporations Act.

La modification a été dûment autorisée conformément aux articles 168 et 170 (selon le cas) de la Loi sur les sociétés par actions.

6. The resolution authorizing the amendment was approved by the shareholders/directors (as applicable) of the corporation on

Les actionnaires ou les administrateurs (selon le cas) de la société ont approuvé la résolution autorisant la modification le

1999 DECEMBER 22

(Year, Month, Day)
(année, mois, jour)

These articles are signed in duplicate.

Les présents statuts sont signés en double exemplaire.

ASTRA PHARMA INC.

(Name of Corporation)
(Dénomination sociale de la société)

By: / Par.

(Signature)
(Signature)

(Description of Office)
(Fonction)

**List of Applications on Which the Name of the Assignee Should Be
Changed from Astra Pharma Inc. to AstraZeneca Canada Inc.**

09/254,227

09/341,016

09/554,326

09/029,633

09/555,576

09/555,579

09/555,580

09/555,575

09/029,468

08/836,830

09/460,722

09/460,723

08/981,700

Assignment to the National Research Council of Canada

Applicant(s): Ahmad, *et al.*
Appl. No.: 09/254,227
Filed: March 3, 1999
For: **G Protein-Coupled Receptors from the Rat and Human** (as amended)


AstraZeneca Canada Inc., a corporation of Canada, having a place of business at 1004 Middlegate Road, Mississauga, Ontario, L4Y 1M4, Canada (hereinafter "AstraZeneca Canada") is owner of right, title and interest in the inventions and discoveries (hereinafter "Inventions") described in the above-identified United States application (hereinafter "Application") by virtue of an Assignment executed by the inventors and recorded in the United States Patent and Trademark Office on January 19, 2000 at Reel 10414, Frame 0583, and a merger document recorded in the United States Patent and Trademark Office on October 12, 2000 at Reel 011217, Frame 0591.

In view of valuable consideration, receipt of which is hereby acknowledged, AstraZeneca Canada hereby assigns and transfers unto the National Research Council of Canada (hereinafter "NRC"), an agency of the Government of Canada, located at 1200 Montreal Road, Bldg. M-58, Ottawa, Ontario, K1A 0R6, Canada, its successors and assigns, AstraZeneca Canada's entire right, title and interest in the Inventions, the Application and all related applications (including all divisions, reissues, continuations, and extensions thereof) and all counterparts in other countries; and any and all Letters Patent (and certificates of invention or similar certificates) (hereinafter "Patents") which may be granted based upon the Inventions or the Application or related applications or counterparts in other countries, said transfer and assignment being applicable throughout the world. AstraZeneca Canada authorizes and requests officials of patent offices in any and all countries of the world to issue

any and all of the Patents, when granted, to NRC, its successors and assigns, as the assignee of AstraZeneca Canada's entire right, title, and interest in and to the same.

ASTRAZENECA CANADA INC.

Date 24 Sept 2003

By 
Bo Hasslev
Director IP Finance and IS

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.